Dr. Lal Pathlabs (LALPATHLAB) Share Price Falls 2.11% Today on NSE
- September 25, 2026
- Posted by: Harsh Piplani
- Category: News
Dr. Lal Pathlabs Share Price declined to Rs 1,920.65 on 25 September 2026, down 2.11% from the previous close of Rs 1,962.10, while the company’s market capitalisation stood at Rs 32,270.61 crore. The move makes Dr. Lal Pathlabs Stock News relevant for investors tracking the stock’s latest share price action, valuation and healthcare sector positioning. The data confirms a clear same-day price fall, but it does not establish any company-specific catalyst. Today’s decline is best read alongside the day’s opening range, the intraday high and low, and the company’s premium valuation versus the broader hospital and healthcare services set. Univest is covering the stock event with a fact-led view for readers following Dr. Lal Pathlabs Share Price Today.
The stock opened at Rs 1,972.15, touched a high of Rs 1,991.30 and a low of Rs 1,916.20 before closing at Rs 1,920.65. The day’s decline of Rs 41.45 came after the stock had already moved below the opening price and spent the session within a relatively narrow band around the lower end of the range. Turnover stood at Rs 3.26 crore. In plain terms, the Dr. Lal Pathlabs Share Price move shows a lower close, a weaker finish versus the day’s opening level and a session that stayed close to the intraday low. Univest readers tracking Dr. Lal Pathlabs Share Price News can use the day’s figures to understand what changed, even though the supplied data does not identify a single trigger.
Dr. Lal Pathlabs (LALPATHLAB) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,920.65 |
| Previous Close | Rs 1,962.1 |
| Today's Move | -Rs 41.45 (-2.11%) |
| Open | Rs 1,972.15 |
| High | Rs 1,991.3 |
| Low | Rs 1,916.2 |
| Turnover | Rs 3.26 crore |
| Market Capitalisation | Rs 32,270.61 crore |
| Market Cap Category | Large Cap |
Dr. Lal Pathlabs Share Price Today finished at Rs 1,920.65 against the previous close of Rs 1,962.10, which means the stock fell Rs 41.45 or 2.11%. The opening price of Rs 1,972.15 was above the close, while the day’s high of Rs 1,991.30 and low of Rs 1,916.20 define the full trading range. That range shows the stock moved between Rs 1,916.20 and Rs 1,991.30 in the session, with the close sitting closer to the low than to the high. Turnover of Rs 3.26 crore provides the traded-value context for the day, and the company remains classified as a Large Cap. For readers searching Dr. Lal Pathlabs Share Price Live or Dr. Lal Pathlabs Share Price Update, the key point is simple: the stock ended lower, and the decline was visible across the day’s price path rather than only at the close. Dr. Lal Pathlabs Stock News therefore centres on the price fall itself, not on any verified external cause.
The share price fall also matters because the stock is now well below the day’s opening price and only marginally above the session low. That makes today’s movement an event-driven update for anyone following Dr. Lal Pathlabs Share Price Today, Dr. Lal Pathlabs Stock Falling Today, or broader Stock Market Today screens. Univest readers should note that the supplied data confirms the move, but does not assign a company-specific reason. The next natural reference point is the company’s financial profile, which helps place the move in valuation context.
Dr. Lal Pathlabs (LALPATHLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 32,270.61 crore |
| P/E Ratio | 60.77x |
| P/B Ratio | 12.6x |
| ROE | 22.37% |
| ROCE | 29.56% |
| EPS | Rs 32.29 |
| Book Value Per Share | Rs 155.67 |
| Dividend Yield | 1.04% |
Dr. Lal Pathlabs Fundamental Analysis shows a company with a market capitalisation of Rs 32,270.61 crore and an enterprise profile reflected in a P/E ratio of 60.77, P/B ratio of 12.6, ROE of 22.37% and ROCE of 29.56%. EPS stands at Rs 32.29 and book value at Rs 155.67 per share. Dividend yield is 1.04%, which provides a historical payout reference against the current share price. These figures are important because they show how the Dr. Lal Pathlabs Share Price is valued in relation to earnings and accounting equity rather than only in relation to the day’s move.
On pure fundamentals, the stock trades at a premium multiple compared with many listed healthcare peers in the same industry set. That does not by itself explain today’s fall, but it does place the Dr. Lal Pathlabs Share Price in a valuation-sensitive zone where investors often compare earnings quality, return ratios and book value closely. Univest’s fact base shows strong return ratios alongside a rich valuation, which makes the Dr. Lal Pathlabs Share Price Today story more about relative pricing than about any one-day operating update. For readers tracking Dr. Lal Pathlabs Latest News, the main takeaway is that today’s price action should be read against a business that remains valued well above book and at a high earnings multiple.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Hospital & Healthcare Services |
| Benchmark Scope | same industry |
| Company P/E Ratio | 60.77x |
| Benchmark Median P/E | 47.11x |
| Benchmark Average P/E | 100.47x |
| Benchmark P/E Range | 6.89x to 1,570.82x |
| Company P/B Ratio | 12.6x |
| Benchmark Median P/B | 3.88x |
| Benchmark Average P/B | 4.76x |
| Company ROE | 22.37% |
| Benchmark Median ROE | 13.01% |
| Benchmark Average ROE | 13.3% |
| Company ROCE | 29.56% |
| Benchmark Median ROCE | 15.84% |
| Benchmark Average ROCE | 3.15% |
| Company Market Capitalisation | Rs 32,270.61 crore |
| Benchmark Median Market Cap | Rs 544.18 crore |
| Benchmark Average Market Cap | Rs 11,770.59 crore |
Sector and Industry Context places Dr. Lal Pathlabs in Healthcare, within the Hospital & Healthcare Services industry. The benchmark scope covers the same industry and includes 65 companies. Against that set, the company’s P/E of 60.77 compares with a benchmark median of 47.11 and an average of 100.47. Its P/B of 12.6 is above the benchmark median of 3.88 and also above the benchmark average of 4.76. ROE of 22.37% is higher than the benchmark median of 13.01%, while ROCE of 29.56% is also above the benchmark median of 15.84% and the benchmark average of 3.15%. The company’s market capitalisation of Rs 32,270.61 crore is far above the benchmark median market cap of Rs 544.18 crore and below the benchmark maximum of Rs 130,272.49 crore.
That comparison matters for Dr. Lal Pathlabs Share Price analysis because it shows the stock sits in the upper end of the industry valuation band, not near the median. The same industry dataset also provides a direct view of peer valuation and returns, which is useful when reading Dr. Lal Pathlabs Share Price News alongside sector context. Univest readers can see that the company’s P/E and P/B are materially above the benchmark medians, while ROE and ROCE are also ahead of the industry medians. The sector itself remains the right frame for interpreting the stock’s valuation rather than the day’s decline alone.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | APOLLOHOSP | 1,30,272.49 | 61.24 | 13.21 | 23.54 | 21.73 |
| Max Healthcare Institute | MAXHEALTH | 1,02,445.77 | 69.98 | 9.33 | 14.53 | 14.97 |
| MANIPAL HEALTH ENTERPRI L | MANIPALHOS | 1,00,021.28 | 109.46 | 5.35 | 12.95 | 13.93 |
| Fortis Healthcare | FORTIS | 67,266.77 | 63.31 | 6.53 | 11.32 | 14.07 |
| Aster DM Healthcare | ASTERDM | 66,295.05 | 210.08 | 15.83 | 13.07 | 16.22 |
Peer Comparison shows Dr. Lal Pathlabs against listed healthcare peers in the same industry. Apollo Hospitals Enterprise has a market cap of Rs 130,272.49 crore, P/E of 61.24, P/B of 13.21, ROE of 23.54% and ROCE of 21.73%. Max Healthcare Institute is at Rs 102,445.77 crore with P/E of 69.98, P/B of 9.33, ROE of 14.53% and ROCE of 14.97%. Fortis Healthcare has Rs 67,266.77 crore market cap, P/E of 63.31, P/B of 6.53, ROE of 11.32% and ROCE of 14.07%.
Against those names, the Dr. Lal Pathlabs Share Price reflects a company with a smaller market capitalisation than the largest listed hospital operators but with valuation ratios that remain high relative to the peer set. Its P/E of 60.77 is close to Apollo Hospitals and below Max Healthcare and Fortis only in a narrow relative sense, while its ROE of 22.37% is ahead of Max Healthcare and Fortis and near Apollo Hospitals. ROCE of 29.56% stands out versus the listed peers provided. For readers searching Dr. Lal Pathlabs Share Price Today or Dr. Lal Pathlabs Stock Analysis, the comparison shows a company that remains richly valued and operationally strong on return ratios, even as the share price falls today.
Why Investors Are Watching Dr. Lal Pathlabs
- The Dr. Lal Pathlabs Share Price fell 2.11% today to Rs 1,920.65 from Rs 1,962.10.
- The day’s low was Rs 1,916.20 and the high was Rs 1,991.30, defining the full trading range.
- Turnover stood at Rs 3.26 crore for the session.
- P/E is 60.77, P/B is 12.6, ROE is 22.37% and ROCE is 29.56%.
- In the same industry set, the company’s valuation sits above the benchmark median on both P/E and P/B.
About Dr. Lal Pathlabs
Dr. Lal Pathlabs operates in Healthcare and the Hospital & Healthcare Services industry. The stock is listed in the Large Cap category and is tracked across NSE and BSE market coverage in Univest’s stock pages. The company’s market capitalisation is Rs 32,270.61 crore. In the supplied dataset, the core financial profile includes P/E, P/B, ROE, ROCE, EPS, book value and dividend yield, which together help frame the company’s current stock news flow. For readers following Dr. Lal Pathlabs Share Price News, the event today is best understood as a market-price move around a business that continues to trade at a premium valuation within its industry.
Track Dr. Lal Pathlabs Share Price on Univest
Use Dr. Lal Pathlabs (LALPATHLAB) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Users can track Dr. Lal Pathlabs Share Price on Univest for live price updates, financial ratios, shareholding pattern, 52-week levels and market insights. Univest also helps readers monitor Dr. Lal Pathlabs Stock News, sector context and peer comparison in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Dr. Lal Pathlabs share price fall today?
Ans. The supplied data confirms a 2.11% decline to Rs 1,920.65, but it does not establish a company-specific catalyst. The movement is best understood from the day’s open, high, low, previous close and turnover.
What is Dr. Lal Pathlabs share price today?
Ans. Dr. Lal Pathlabs Share Price Today stood at Rs 1,920.65, down Rs 41.45 from the previous close of Rs 1,962.10. The stock traded between Rs 1,916.20 and Rs 1,991.30 during the session.
Is Dr. Lal Pathlabs a Large Cap stock?
Ans. Yes. The company is classified as a Large Cap in the supplied dataset, with a market capitalisation of Rs 32,270.61 crore. That size context helps frame Dr. Lal Pathlabs Stock News.
How does Dr. Lal Pathlabs compare with healthcare peers?
Ans. The company’s P/E of 60.77 and P/B of 12.6 sit above the industry benchmark median. Its ROE of 22.37% and ROCE of 29.56% are also above the benchmark medians in the same industry.
What do Dr. Lal Pathlabs EPS and book value show?
Ans. EPS is Rs 32.29 and book value is Rs 155.67 per share. EPS reflects earnings per share, while book value shows accounting net worth per share. Both add context to the current valuation.
What should investors watch next in Dr. Lal Pathlabs Share Price?
Ans. Investors may watch whether the stock stays near today’s close of Rs 1,920.65, how it trades against its sector valuation, and whether the company’s premium P/E and P/B remain supported by return ratios.
